Wild Biotech co-founder Neta Raab

Two Church lab vets, a se­cre­tive in­sti­tute and an Is­raeli bil­lion­aire hunt for drugs in the guts of wild an­i­mals

Over the last four years, Ne­ta Raab and Ido Bachelet have re­ceived hun­dreds of padded card­board box­es con­tain­ing frozen poop from wild an­i­mals on five dif­fer­ent con­ti­nents.

The pack­ages came reg­u­lar­ly to their lab out­side Tel Aviv, sent from a squad of zo­ol­o­gists and spe­cial­ized Is­raeli army vet­er­ans who tracked enough an­i­mals to fill a Rud­yard Kipling nov­el, rush­ing to col­lect vul­ture and rhi­no and frog sam­ples with­in an hour of ex­tru­sion. Raab and Bachelet care­ful­ly opened the box­es, re­mov­ing the sam­ples from plas­tic-wrapped tubes and then us­ing spe­cial­ized mag­net­ic beads to fish out the bac­te­r­i­al DNA in­side for se­quenc­ing.

The re­sult of that ef­fort ap­peared Thurs­day in Sci­ence, where Raab, Bachelet and promi­nent Is­raeli com­pu­ta­tion­al bi­ol­o­gist Er­an Se­gal pub­lished what amounts to the largest data­base ever as­sem­bled of the mi­cro­bio­me, or gut bac­te­ria, in­side dif­fer­ent mem­bers of the an­i­mal king­dom. Sam­pling near­ly 200 an­i­mals, they doc­u­ment­ed 5,000 genomes across over 1,200 dif­fer­ent bac­te­r­i­al species, most of which had nev­er been seen be­fore.

Jack Gilbert

It’s a ma­jor sci­en­tif­ic achieve­ment, out­side ex­perts say, one that will al­low the grow­ing num­ber of re­searchers study­ing the mi­cro­bio­me in­side par­tic­u­lar an­i­mals, in­clud­ing hu­mans, to fit their find­ings in­to a broad­er con­text. But for Raab and Bachelet, two vet­er­ans of the George Church Lab, it’s al­so a vast trove of ge­net­ic in­for­ma­tion that could be mined for new drugs on a long list of dis­eases.

They’ve launched a com­pa­ny, Wild Biotech, to be­gin turn­ing the genes they found in­to ther­a­pies for im­muno­log­i­cal, in­flam­ma­to­ry and gas­troin­testi­nal con­di­tions. The idea is that these bac­te­ria have, over mil­lions of years, evolved pro­teins to car­ry out a wide range of unique func­tions for their hosts. Tap­ping and en­gi­neer­ing those pro­teins could help cor­rect prob­lems in hu­mans.

“This re­source re­al­ly does cre­ate a plat­form — a spring­board if you will — to ac­cel­er­ate re­search, to help us lever­age the mi­cro­bio­me in treat­ing dis­ease, im­prov­ing health, restor­ing ecosys­tems,” says Jack Gilbert, a mi­cro­bial ecol­o­gist at UC San Diego who is not in­volved in the re­search or the com­pa­ny.

Time­wise, he adds, bac­te­ria have a leg up on any med­i­c­i­nal chemist in a drug lab. “If you think about it, na­ture has been ex­per­i­ment­ing with vari­ants in mi­cro­bial chem­istry for bil­lions of years,” he says. “That’s a lot of ex­per­i­men­ta­tion — way more than any hu­man en­deav­or could hope to achieve.”

Dan Littman

Wild Biotech joins the long list of com­pa­nies that have raised bil­lions to lever­age sci­en­tists’ grow­ing un­der­stand­ing of the hu­man mi­cro­bio­me in­to new drugs for can­cer or in­fec­tious dis­ease. Those ef­forts, though, have large­ly fo­cused on giv­ing peo­ple tablets con­tain­ing strains of liv­ing bac­te­ria from hu­mans, re­ly­ing on the con­flu­ence of hun­dreds of dif­fer­ent genes to re­store a healthy im­mune sys­tem.

In try­ing to tap an­i­mal mi­cro­bio­mes and iso­late in­di­vid­ual pro­teins, Raab and Bachelet will have to show a deep­er un­der­stand­ing of the bac­te­ria and the func­tion of the genes they un­cov­ered. They say they have that tech­nol­o­gy and they’ve re­ceived an em­i­nent backer in Is­raeli bil­lion­aire Mar­ius Nacht, but so far, it re­mains un­pub­lished and un­proven.

“My guess is that there’s gonna be a lot of valu­able med­i­c­i­nal in­for­ma­tion in there,” says Dan Littman, a pro­fes­sor of mol­e­c­u­lar im­munol­o­gy at NYU and co-founder of the mi­cro­bio­me biotech Vedan­ta. “But it’s go­ing to take an enor­mous amount of work to go from here to the next step of mak­ing a valu­able prod­uct.”

A hye­na cre­at­ing a mi­cro­bio­me sam­ple in Ugan­da. Re­searchers will col­lect it with­in the hour (Gal Zanir)

Click on the im­age to see the full-sized ver­sion

A se­cre­tive Is­raeli in­sti­tute with some bird ques­tions

Wild Biotech grew out of work Raab, Bachelet and their third co­founder, Doron Levin, con­duct­ed at a small in­sti­tute in Re­hovot, Is­rael called Aug­man­i­ty. Bachelet did his post­doc at the Church lab, where he start­ed mak­ing a name in a field of nan­otech­nol­o­gy called DNA origa­mi, and he says he found­ed Aug­man­i­ty af­ter leav­ing acad­e­mia to back am­bi­tious sci­en­tif­ic projects. But he of­fered no oth­er de­tails, in­clud­ing what oth­er work they do or how many peo­ple work there.

“We’re a very stealthy or­ga­ni­za­tion,” Bachelet says, point­ing me to a sin­gle-page web­site that was of­fline at the time. “There’s no sign on the build­ing, there’s no sign on the door.”

Raab, a for­mer stu­dent and now Wild’s CEO, joined Aug­man­i­ty af­ter her own stint at the Church lab, hop­ing to help build Is­rael’s biotech scene.

The mi­cro­bio­me project arose out of sev­er­al ideas they had about birds: Is­rael is a land­ing spot for bil­lions of birds mi­grat­ing be­tween Africa and Eu­rope — could they sam­ple their drop­pings and warn coun­tries of the path­o­gen­ic bac­te­ria they car­ry? They al­so won­dered about the mi­cro­bio­mes in vul­tures and oth­er scav­engers. These an­i­mals eat rot­ting flesh, so they need to evade or with­stand the tox­ins in the bac­te­ria that grow on corpses. Did they use their own mi­cro­bio­mes to do so?

Soon, they were ask­ing about all sorts of dif­fer­ent an­i­mals and how they sur­vived con­di­tions hu­mans nev­er en­counter. “So the idea was born from many dif­fer­ent small ques­tions,” Raab says. “But at some point, we kind of had an epiphany.”

Raab worked with ex­perts from the Is­raeli sa­fari and IDF spe­cial­ists to track an­i­mals in Hun­gary, Ugan­da, the Falk­land Is­lands, Mada­gas­car, Aus­tralia and Is­rael. They used drones to fol­low an­i­mals and teamed with guides and rangers to track them by foot and ve­hi­cle. They put up nets to trap and band birds. They board­ed in­flat­able boats to trail whales off the Falk­land Is­lands, skim­ming sam­ples on the wa­ter’s sur­face.

Along with the fe­cal sam­ple, track­ers al­so logged de­tails about the in­di­vid­ual an­i­mal and lo­ca­tion. Oth­er re­searchers have looked at a wide range of cap­tive an­i­mals, but Raab want­ed wild an­i­mals, point­ing to re­search that cap­tiv­i­ty can change or even crip­ple an an­i­mal’s mi­cro­bio­me.

“It changes their ca­pac­i­ty to re­turn to na­ture,” she says. “And we re­al­ly want­ed to look for the spe­cif­ic fea­tures that en­able them to re­al­ly sur­vive in the hos­tile and harsh en­vi­ron­ments.”

To an­a­lyze the sam­ples af­ter they ar­rived in Is­rael, Bachelet and Raab reached out to Se­gal, a pi­o­neer in com­pu­ta­tion­al ge­net­ics who some­times worked on the hu­man mi­cro­bio­me. The two labs broke the DNA they ex­tract­ed — a tan­gle of strands from all the var­i­ous mi­crobes in a giv­en fe­cal sam­ple called a “metagenome” —  in­to small pieces that can be read by a se­quencer. The se­quencer spits out an in­com­pre­hen­si­ble jum­ble of frag­ments from hun­dreds or thou­sands of dif­fer­ent bac­te­ria. But by look­ing for places where the dif­fer­ent frag­ments over­lap, the re­searchers can stitch com­plete genomes back to­geth­er.

They can then tag in­di­vid­ual genes by look­ing for rec­og­niz­able pat­terns. Every gene, for ex­am­ple, starts and ends with string of let­ters called a “start” and “stop” codon.

“A metagenome is like an in­com­plete jig­saw puz­zle thrown on the floor,” says Gilbert, the UCSD re­searcher. “What they’ve done is take those puz­zle pieces and start to piece them to­geth­er.”

Sur­pris­ing in­sights

The work im­me­di­ate­ly brought sur­pris­es. David Zee­vi, a PhD stu­dent at Se­gal’s lab who worked on the metagenome analy­sis, says bac­te­ria that live on land and in the sea gen­er­al­ly have sim­i­lar genomes. So he was shocked by how much the mi­cro­bio­mes could vary be­tween species and how many new genes ap­peared.

“They have such a huge di­ver­si­ty, huge po­ten­tial of new mi­cro­bial genes,” says Zee­vi, who is now an in­de­pen­dent fel­low at Rock­e­feller about to launch his own mi­cro­bio­me lab at the Weiz­mann In­sti­tute. “What are the se­lec­tive pres­sures, in terms of evo­lu­tion, that led to some­thing like this?”

For Bachelet and Raab, though, the big ques­tion is whether they can trans­late the data­base in­to drugs. They be­gan link­ing the genes they found to traits in the pa­per, show­ing for ex­am­ple dif­fer­ences be­tween car­ni­vores and her­bi­vores that might give meat-eaters en­hanced abil­i­ties to com­bat tox­ic bac­te­ria.

As a proof-of-con­cept, they syn­the­sized one pro­tein found in grif­fon vul­tures’ mi­cro­bio­me they be­lieved helped it com­bat the dead­ly synapse-cut­ting poi­son bot­u­linum tox­in A. It turned out that the pro­tein ac­tu­al­ly sped up the tox­in’s ef­fect — part of what the re­searchers be­lieve is a cas­cade of en­zymes grif­fons use to clear it.

Bot­u­linum tox­in A is al­so the key in­gre­di­ent in Ab­b­Vie bil­lion-dol­lar Botox. Per­haps, Bachelet says, you can use the grif­fon pro­tein to cre­ate a fast-act­ing Botox, or “Su­per-Botox.” “That’s al­ready a mar­ket,” he says.

Naa­ma Ge­va Za­torsky

Naa­ma Ge­va-Za­torsky, who runs a sys­tems bi­ol­o­gy lab at the Tech­nion, agreed the tox­in pro­vid­ed a good test case, adding that she’d now like to see larg­er work on col­lect­ing, study­ing and freez­ing an­i­mal mi­cro­bio­me sam­ples, as re­searchers have done with hu­man mi­cro­bio­mes.

“This is a pure­ly beau­ti­ful study!” she said in an email. “Trans­lat­ing to med­i­cine is to­tal­ly fea­si­ble.”

Not every­one is con­vinced, though. David Berry, a part­ner at Flag­ship who played a piv­otal role in found­ing the mi­cro­bio­me biotechs Seres Ther­a­peu­tics, Evelo Bio­sciences and In­di­go Agri­cul­ture, says their work brought ma­jor in­sights in­to an un­der-ex­plored area. In the past, though, he says re­searchers have strug­gled to iso­late in­di­vid­ual genes that give a par­tic­u­lar gut bac­teri­um its im­pact.

David Berry

Of­ten­times, sci­en­tists would see two strains of the same species, one that has a pro­found ef­fect on its host and one that doesn’t. But when they tried to com­pare the two genomes to find the dif­fer­ence, they would find mil­lions of dif­fer­ences — on the same scale that sep­a­rates hu­man and ba­nanas, say, or hu­mans and fun­gi — mak­ing it im­pos­si­ble to sin­gle out a pro­tein that could be ther­a­peu­tic.

Still, he adds, some­times they found chem­i­cals pro­duced by the mi­crobes that were piv­otal.

“I wouldn’t rule out the po­ten­tial that there’s some­thing deeply im­por­tant and deeply in­sight­ful in the da­ta,” he says. “But I think there’s a whole bunch of steps that have to be tak­en to turn this in­to some­thing that can pro­duce drugs.”

A wild fu­ture 

Bachelet and Raab are now work­ing on those steps. So far they’re keep­ing most de­tails about the com­pa­ny un­der wraps. They say they have a far larg­er data­base than the one they pub­lished in Sci­ence and an AI-as­sist­ed soft­ware that can link the in­di­vid­ual genes they found to po­ten­tial im­pact par­tic­u­lar dis­or­ders.

They’re fo­cus­ing, Bachelet says, on pro­teins and func­tions you can’t find in the hu­man mi­cro­bio­me and that might of­fer new routes of ad­min­is­tra­tion or the abil­i­ty to rad­i­cal­ly al­ter the im­mune sys­tem. With bil­lion­aire Nacht’s back­ing, they’ve built a 9-per­son-team with­out hav­ing to re­ly on tra­di­tion­al VC fund­ing.

The com­pa­ny has a cou­ple lead can­di­dates from the ini­tial analy­sis and they’ll work on ex­pand­ing the plat­form and re­fin­ing the soft­ware for at least the next year, be­fore they po­ten­tial­ly need more fund­ing. In the mean­time, they’ve frozen all their old sam­ples should they need to be test­ed again or if they want to try to cul­ture in­di­vid­ual strains liv­ing in­side. It’s a one-of-a-kind re­source for the fu­ture.

“We’re heads down,” Raab says. “It’s ear­ly, still.”

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

Ireland has been on a roll in 2022, with several large pharma companies announcing multimillion-euro projects. Now AstraZeneca’s rare disease outfit Alexion is looking to get in on the action.

Alexion on Friday announced a €65 million ($68.8 million) investment in new and enhanced capabilities across two sites in the country, including at College Park in the Dublin suburb of Blanchardstown and the Monksland Industrial Park in the central Irish town of Athlone, according to the Industrial Development Agency of Ireland.

State bat­tles over mifepri­s­tone ac­cess could tie the FDA to any post-Roe cross­roads

As more than a dozen states are now readying so-called “trigger” laws to kick into effect immediate abortion bans following the overturning of Roe v. Wade on Friday, these laws, in the works for more than a decade in some states, will likely kick off even more legal battles as states seek to restrict the use of prescription drug-based abortions.

Since Friday’s SCOTUS opinion to overturn Americans’ constitutional right to an abortion after almost 50 years, reproductive rights lawyers at Planned Parenthood and other organizations have already challenged these trigger laws in Utah and Louisiana. According to the Guttmacher Institute, other states with trigger laws that could take effect include Arkansas, Idaho, Kentucky, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, and Wyoming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Deborah Dunsire, Lundbeck CEO

Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

Five years after Lundbeck and their longtime collaborators at Otsuka turned up a mixed set of Phase III data for Rexulti as a treatment for Alzheimer’s dementia-related agitation, they’ve come through with a new pivotal trial success they believe will finally put them on the road to an approval at the FDA. And if they’re right, some analysts believe they’re a short step away from adding more than $500 million in annual sales for the drug, already approved in depression and schizophrenia.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

A Mer­ck part­ner is sucked in­to the fi­nan­cial quag­mire as key lender calls in a note

Another biotech standing on shaky financial legs has fallen victim to the bears.

Merck partner 4D Pharma has reported that a key lender, Oxford Finance, shoved the UK company into administration after calling in a $14 million loan they couldn’t immediately make good on. Trading in their stock was halted with a market cap that had fallen to a mere £30 million.

“Despite the very difficult prevailing market conditions,” 4D reported on Friday, the biotech had been making progress on finding some new financing and turned to Oxford with an alternative late on Thursday and then again Friday morning.

Members of the G7 from left to right: Prime Minister of Italy Mario Draghi, European Commission President Ursula von der Leyen, President Joe Biden, German Chancellor Olaf Scholz, British Prime Minister Boris Johnson, Canadian Prime Minister Justin Trudeau, Prime Minister of Japan Fumio Kishida, French President Emmanuel Macron and European Council President Charles Michel (AP Photo/Susan Walsh)

Biden and G7 na­tions of­fer funds for vac­cine and med­ical prod­uct man­u­fac­tur­ing project in Sene­gal

Amidst recently broader vaccine manufacturing initiatives from the EU and European companies, the G7 summit in the mountains of Bavaria has brought about some positive news for closing vaccine and medical product manufacturing gaps around the globe.

According to a statement from the White House, the G7 leaders have formally launched the partnership for global infrastructure, PGII. The effort will aim to mobilize hundreds of billions of dollars to deliver infrastructure projects in several sectors including the medical and pharmaceutical manufacturing space.

Fed­er­al judge de­nies Bris­tol My­er­s' at­tempt to avoid Cel­gene share­hold­er law­suit

Some Celgene shareholders aren’t happy with how Bristol Myers Squibb’s takeover went down.

On Friday, a New York federal judge ruled that they have a case against the pharma giant, denying a request to dismiss allegations that it purposely slow-rolled Breyanzi’s approval to avoid paying out $6.4 billion in contingent value rights (CVR).

When Bristol Myers put down $74 billion to scoop up Celgene back in 2019, liso-cel — the CAR-T lymphoma treatment now marketed as Breyanzi — was supposedly one of the centerpieces of the deal. After going back and forth on negotiations for about six months, BMS put $6.4 billion into a CVR agreement that required an FDA approval for Zeposia, Breyanzi and Abecma, each by an established date.

Chris Anzalone, Arrowhead CEO

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

Almost two years after Takeda wagered $300 million cash to partner with Arrowhead on an RNAi therapy for a rare disease, the companies are spelling out Phase II data that they believe put them one step closer to their big dreams.

In a small, open label study involving only 16 patients who had liver disease associated with alpha-1 antitrypsin deficiency (AATD), Arrowhead’s candidate — fazirsiran, previously ARO-AAT — spurred substantial reductions in accumulated mutant AAT protein in the liver, a hallmark of the condition. Investigators also tracked improvements in symptoms, with seven out of 12 who received the high, 200 mg dose seeing regression of liver fibrosis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

No stranger to gene ther­a­py woes, Astel­las runs in­to an­oth­er safe­ty-re­lat­ed clin­i­cal hold

Astellas Pharma, which has been at the forefront of uncovering the risks associated with gene therapies delivered by adeno-associated viruses, must take another safety alarm head-on.

The FDA has slapped a clinical hold on Astellas’ Phase I/II trial of a gene therapy candidate for late-onset Pompe disease, after investigators flagged a serious case of peripheral sensory neuropathy.

It marks the latest in a streak of setbacks Astellas has encountered since making a splashy entry into the gene therapy space with its $3 billion buyout of Audentes. But the lead program, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), had to be halted more than once after a total of four patients died in the trial — and the scientific community still doesn’t have all the answers of what caused the deaths.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.